Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

BCNU-associated pneumonitis: portrait of a toxicity.

Till BG, Madtes DK.

Leuk Lymphoma. 2012 Jun;53(6):1019-20. doi: 10.3109/10428194.2011.654341. Epub 2012 Jan 31. No abstract available.

PMID:
22220936
[PubMed - indexed for MEDLINE]
2.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.

Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB.

Leuk Lymphoma. 2012 Jun;53(6):1130-6. doi: 10.3109/10428194.2011.645208. Epub 2012 Jan 3.

PMID:
22132836
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.

Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.

J Clin Oncol. 1994 Sep;12(9):1890-901.

PMID:
7916039
[PubMed - indexed for MEDLINE]
Free Article
4.

High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.

Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE.

Bone Marrow Transplant. 1996 Mar;17(3):335-40.

PMID:
8704683
[PubMed - indexed for MEDLINE]
5.

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.

Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL.

Bone Marrow Transplant. 1999 Jun;23(11):1131-8.

PMID:
10382952
[PubMed - indexed for MEDLINE]
Free Article
6.

High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.

Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, et al.

Blood. 1995 Jul 15;86(2):451-6.

PMID:
7541661
[PubMed - indexed for MEDLINE]
Free Article
7.

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.

Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al.

J Clin Oncol. 1993 Jun;11(6):1085-91.

PMID:
8099120
[PubMed - indexed for MEDLINE]
Free Article
8.

Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.

Fassas A, Gojo I, Rapoport A, Cottler-Fox M, Meisenberg B, Papadimitriou JC, Tricot G.

Bone Marrow Transplant. 2001 Aug;28(4):399-403.

PMID:
11571514
[PubMed - indexed for MEDLINE]
Free Article
9.

Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.

Carlson K, Smedmyr B, Hagberg H, Oberg G, Simonsson B.

Bone Marrow Transplant. 1993 Mar;11(3):205-8.

PMID:
8467284
[PubMed - indexed for MEDLINE]
10.
11.

High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.

van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al.

Bone Marrow Transplant. 1995 Apr;15(4):549-55.

PMID:
7655380
[PubMed - indexed for MEDLINE]
12.

A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.

Jang GD, Kim SW, Suh CW, Kim EK, Bahng HS, Jeong YH, Park IG, Kim WK, Kim SH, Suh EJ, Park CJ, Ji HS, Lee JS.

J Korean Med Sci. 2002 Aug;17(4):555-9.

PMID:
12172056
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, et al.

J Clin Oncol. 1990 Apr;8(4):648-56.

PMID:
2313334
[PubMed - indexed for MEDLINE]
Free Article
14.

BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.

Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21.

PMID:
17710401
[PubMed - indexed for MEDLINE]
15.

delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.

Gonçalves TL, Benvegnú DM, Bonfanti G, Frediani AV, Rocha JB.

Pharmacol Res. 2009 Apr;59(4):279-84. doi: 10.1016/j.phrs.2008.12.005. Epub 2008 Dec 30.

PMID:
19162187
[PubMed - indexed for MEDLINE]
16.

High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.

Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.

Bone Marrow Transplant. 2004 Oct;34(7):581-7.

PMID:
15273714
[PubMed - indexed for MEDLINE]
17.

High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.

Patti C, Majolino I, Scimè R, Indovina A, Vasta S, Liberti G, Gentile S, Santoro A, Pisa R, Caronia F.

Eur J Haematol. 1993 Jul;51(1):18-24.

PMID:
8348940
[PubMed - indexed for MEDLINE]
18.
19.

BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C.

Leuk Res. 2011 Feb;35(2):183-7. doi: 10.1016/j.leukres.2010.07.016. Epub 2010 Aug 3.

PMID:
20684990
[PubMed - indexed for MEDLINE]
20.

Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.

Knauf WU, Koenigsmann MP, Notter M, Hoppe B, Reufi B, Oberberg D, Thiel E, Berdel WE.

Leuk Lymphoma. 1996 Oct;23(3-4):305-11.

PMID:
9031111
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk